AU403

AU403 (1-20 μM; 24 h) exhibits potent, dose-dependent activation of LXRβ, with an EC₅₀ of 45 nM, while demonstrating significantly reduced potency toward LXRα (EC₅₀ = 400 nM) in HEK293 cells^[1].
AU403 (1-20 μM; 24 h) exhibits partial agonistic activity at PPARδ (EC₅₀ ∼ 40 nM), exhibits weak activity toward PPARα (EC₅₀ ∼ 10 μM) and shows moderate agonistic activity toward PPARγ (EC₅₀ of ∼ 350 nM) in HEK293 cells^[1].
AU403 (1-20 μM; 24 h) robustly induces promoter activity and drive key cholesterol transporters in HEK293 cells^[1].
AU403 (5-20 μM; 24 h) modulates pathways central to hepatocyte biology, including cytochrome P450 (CYP) enzymes, lipid metabolism, and cholesterol homeostasis, without promoting the transcription of key lipogenic drivers (FASN and SREBF1) in human primary hepatocytes, thereby successfully mitigating the lipogenic risks associated with LXR activation ^[1].
AU403 (0.01-100 μM) has no significant effect on neutropenia or total erythroid levelsat its LD₅₀ of 55 μM, while preserving hematopoietic progenitor cell activity without impacting erythropoiesis in bone marrow-derived erythroid progenitor cells^[1]. AU403 exhibits no cardiotoxic effect in the hERG assay, with an IC₅₀ of 22 μM^[1].
AU403 (1-10 μM) significantly reduces Aβ secretion, and this mechanism may work in concert with the upregulation of ABC transporters to promote the clearance of Aβ plaques in APP-CHO cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.